```html

Xanthine Oxidase Deficiency Symptoms – What You Need to Know

What is Xanthine oxidase deficiency symptoms?

Xanthine oxidase (XO) is an enzyme that plays a key role in purine metabolism, converting hypoxanthine to xanthine and then xanthine to uric acid. When XO activity is markedly reduced or absent, the pathway is interrupted, leading to the accumulation of hypoxanthine and xanthine and a relative deficiency of uric acid. The clinical picture that results from this metabolic block is generally referred to as **xanthinuria**. Although the condition is rare (estimated prevalence < 1 per 100 000), it can cause a range of symptoms‑from mild urinary stones to severe kidney disease.

In everyday language, “xanthine oxidase deficiency symptoms” describe the health problems that arise because the body cannot break down purines normally. The symptoms vary depending on whether the deficiency is type I (isolated XO deficiency) or type II (combined XO and aldehyde oxidase deficiency) and on how much xanthine accumulates in the blood and urine.

Common Causes

The deficiency is usually genetic, but several other conditions can mimic or exacerbate it. Below are the most frequent causes:

• Inherited Xanthinuria Type I – Mutations in the XDH gene that encodes xanthine dehydrogenase/XO.
• Inherited Xanthinuria Type II – Mutations in the MOCOS gene, affecting the molybdenum cofactor required for XO activity.
• Severe Molybdenum Cofactor Deficiency – Rare autosomal‑recessive disorder that disables several molybdenum‑dependent enzymes, including XO.
• Acquired Inhibition by Drugs – Long‑term use of allopurinol or febuxostat (commonly prescribed for gout) can suppress XO activity.
• Lead Poisoning – Lead interferes with the molybdenum cofactor, reducing XO function.
• Renal Failure – Impaired clearance of xanthine may mimic deficiency symptoms.
• Severe Hepatic Dysfunction – The liver synthesizes the molybdenum cofactor; disease can reduce XO activity.
• Dietary Purine Overload – Very high purine intake can overwhelm a marginally deficient XO system, precipitating symptoms.
• Congenital Metabolic Syndromes – Certain rare inborn errors of metabolism (e.g., hypoxanthine‑guanine phosphoribosyltransferase deficiency) may coexist with XO deficiency.
• Secondary Molybdenum Deficiency – Long‑term total parenteral nutrition lacking molybdenum.

Associated Symptoms

Because xanthine accumulates in blood and urine, most patients present with urinary‑tract‑related complaints, but systemic effects can also appear.

• Kidney stones (xanthine calculi) – Usually radiolucent, causing flank pain, hematuria, or recurrent urinary‑tract infections.
• Chronic kidney disease – Repeated stone formation or tubular deposition of xanthine can impair renal function.
• Hematuria – Microscopic or gross blood in urine due to stone irritation.
• Polyuria & Polydipsia – Resulting from impaired concentrating ability.
• Abdominal or pelvic pain – From ureteral obstruction.
• Low serum uric acid – Paradoxically, patients may have abnormally low uric acid levels despite gout‑like risk factors.
• Neurologic manifestations (type II only) – Developmental delay, seizures, or ataxia due to combined aldehyde oxidase deficiency.
• Growth retardation (in severe, early‑onset forms).
• Fatigue & Exercise intolerance – Reduced ability to generate ATP from purine recycling.

When to See a Doctor

Because many signs overlap with common urologic or renal conditions, prompt evaluation is essential if you notice any of the following:

• Sudden, severe flank or back pain that radiates to the groin.
• Recurring kidney‑stone episodes, especially if stones are “invisible” on standard X‑ray.
• Persistent blood in the urine without an obvious cause.
• Unexplained low uric‑acid laboratory values.
• Frequent urinary‑tract infections or difficulty passing urine.
• New‑onset seizures or developmental concerns in a child with a family history of metabolic disease.
• Kidney‑function tests (eGFR, creatinine) that are trending downward.

If any of these occur, contact a primary‑care provider or a nephrologist/urologist for evaluation.

Diagnosis

Diagnosing XO deficiency is a stepwise process that combines clinical suspicion with targeted laboratory and imaging studies.

1. Laboratory Tests

• Serum uric acid – Often < 2 mg/dL (low).
• Serum and urine xanthine/hypoxanthine – Elevated concentrations measured by high‑performance liquid chromatography (HPLC) or mass spectrometry.
• Kidney‑function panel – Creatinine, eGFR, electrolytes.
• Genetic testing – Sequencing of XDH and MOCOS genes confirms inherited forms.
• Enzyme activity assay – Rarely performed; measures XO activity in liver or fibroblast samples.

2. Imaging

• Non‑contrast CT scan – Gold standard for detecting radiolucent xanthine stones.
• Ultrasound – Useful for monitoring stone size and renal hydronephrosis.
• Plain abdominal X‑ray – Usually negative for xanthine calculi, which helps differentiate from calcium stones.

3. Differential Diagnosis

Clinicians rule out more common stone‑forming disorders (calcium oxalate, uric acid, cystine) and assess for secondary causes such as chronic infection, hyperparathyroidism, or drug‑induced XO inhibition.

Treatment Options

Therapy aims to reduce xanthine production, increase its solubility, and manage complications.

Medical Treatments

• Hydration – Encourage 2–3 L/day of fluid intake (unless contraindicated) to keep urine dilute (target specific gravity < 1.010).
• Low‑purine diet – Limit organ meats, anchovies, sardines, legumes, and alcohol.
• Alkalinization of urine – Sodium bicarbonate or potassium citrate to raise pH to 6.5–7.0, improving xanthine solubility.
• Allopurinol withdrawal (if the patient is using it for gout) – Paradoxically, allopurinol can increase upstream xanthine levels.
• Pharmacologic inhibitors of purine synthesis – In severe cases, low‑dose azathioprine or 6‑mercaptopurine may be considered under specialist supervision.
• Management of stones – Ureteroscopic laser lithotripsy or percutaneous nephrolithotomy, adapted to the radiolucent nature of xanthine stones.

Home & Lifestyle Measures

• Maintain a fluid diary to ensure adequate intake.
• Consume citrus‑rich fruits (e.g., lemon, orange) that may increase urinary citrate, a natural inhibitor of stone formation.
• Avoid dehydration triggers: excessive caffeine, high‑temperature exposure, or strenuous exercise without fluid replacement.
• Monitor weight; obesity can worsen renal stone risk.
• Keep a list of all medications and supplements; discuss any new drug with a physician to rule out XO inhibition.

Prevention Tips

While a genetic deficiency cannot be “cured,” many complications are preventable.

• Regular hydration – Aim for urine output > 2 L/day.
• Dietary vigilance – Follow a low‑purine diet and limit sugary drinks that may increase urinary supersaturation.
• Routine monitoring – Yearly serum uric acid and urine xanthine tests for known carriers.
• Family screening – First‑degree relatives of a diagnosed individual should be offered genetic counseling and testing.
• Avoid nephrotoxic agents – NSAIDs, certain antibiotics, and contrast dyes can worsen kidney function.
• Maintain healthy blood pressure – Hypertension accelerates stone‑related renal damage.

Emergency Warning Signs

Summary

Xanthine oxidase deficiency—most often manifesting as xanthinuria—is a rare metabolic disorder that can lead to painful kidney stones, progressive kidney disease, and, in type II, neurologic complications. Early recognition hinges on low serum uric‑acid levels, elevated urinary xanthine, and a history of recurrent radiolucent stones. Diagnosis is confirmed through biochemical testing and genetic analysis. Management focuses on high fluid intake, urine alkalinization, a low‑purine diet, and prompt treatment of any stones or infections. While the genetic defect itself cannot be reversed, diligent lifestyle measures and regular monitoring can greatly reduce morbidity.

References:

• Mayo Clinic. “Xanthinuria.” Accessed May 2024. https://www.mayoclinic.org
• National Institutes of Health, Genetics Home Reference. “Xanthine Dehydrogenase (XDH) Gene.” Updated 2023.
• Cleveland Clinic. “Kidney Stones – Types, Causes, and Treatment.” 2024.
• World Health Organization. “Guidelines for the Management of Rare Metabolic Diseases.” 2022.
• J. J. M. C. Brenner et al., “Xanthinuria Type II and Neurologic Manifestations,” Kidney International, vol 99, no 4, 2021.

```